AU2017321708B2 - Methods and compositions for treating diseases and disorders of the nervous system - Google Patents

Methods and compositions for treating diseases and disorders of the nervous system Download PDF

Info

Publication number
AU2017321708B2
AU2017321708B2 AU2017321708A AU2017321708A AU2017321708B2 AU 2017321708 B2 AU2017321708 B2 AU 2017321708B2 AU 2017321708 A AU2017321708 A AU 2017321708A AU 2017321708 A AU2017321708 A AU 2017321708A AU 2017321708 B2 AU2017321708 B2 AU 2017321708B2
Authority
AU
Australia
Prior art keywords
seq
dreadd
agonist
disease
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017321708A
Other languages
English (en)
Other versions
AU2017321708A1 (en
Inventor
Gary Aston-Jones
Hannah E. Bowrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of AU2017321708A1 publication Critical patent/AU2017321708A1/en
Application granted granted Critical
Publication of AU2017321708B2 publication Critical patent/AU2017321708B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
AU2017321708A 2016-08-31 2017-08-31 Methods and compositions for treating diseases and disorders of the nervous system Active AU2017321708B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381883P 2016-08-31 2016-08-31
US62/381,883 2016-08-31
PCT/US2017/049629 WO2018045178A1 (en) 2016-08-31 2017-08-31 Methods and compositions for treating diseases and disorders of the nervous system

Publications (2)

Publication Number Publication Date
AU2017321708A1 AU2017321708A1 (en) 2019-03-14
AU2017321708B2 true AU2017321708B2 (en) 2024-01-04

Family

ID=61301702

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017321708A Active AU2017321708B2 (en) 2016-08-31 2017-08-31 Methods and compositions for treating diseases and disorders of the nervous system

Country Status (5)

Country Link
US (2) US11542315B2 (https=)
EP (1) EP3507371B1 (https=)
JP (1) JP7186702B2 (https=)
AU (1) AU2017321708B2 (https=)
WO (1) WO2018045178A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
EP3773723A1 (en) * 2018-04-13 2021-02-17 BlumenTech S.L. Combination product for the induction and/or maintenance of general anesthesia
KR20210050493A (ko) * 2018-05-25 2021-05-07 더 칠드런스 메디칼 센터 코포레이션 척수 손상의 치료 방법
JP2022512622A (ja) * 2018-10-05 2022-02-07 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 改変受容体を含む血小板の作製方法及びその使用法
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
AU2020228289B2 (en) 2019-02-27 2026-02-05 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
GB202002073D0 (en) * 2020-02-14 2020-04-01 Ucl Business Ltd Horizontal cells
WO2022097764A1 (ko) * 2020-11-04 2022-05-12 전남대학교병원 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물
JP2024519329A (ja) 2021-05-12 2024-05-10 ユーシーエル ビジネス リミテッド 合成受容体
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
US11980603B2 (en) 2022-06-11 2024-05-14 AMS Therapeutics, LLC Method of treating expressive language deficit in autistic humans
WO2024182608A2 (en) * 2023-03-01 2024-09-06 Gateway Biotechnology, Inc. Chemogenetics-based therapy for neurological disorders
TWI883819B (zh) * 2024-02-06 2025-05-11 陸汝斌 組合物用於製備改善認知能力之藥物的用途
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015136247A1 (en) * 2014-03-13 2015-09-17 Ucl Business Plc Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003214920A1 (en) * 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
US9758833B2 (en) 2008-02-19 2017-09-12 The Johns Hopkins University Methods for predicting esophageal adenocarcinoma (EAC)
WO2016161124A1 (en) 2015-03-31 2016-10-06 New York University Compositions and method for reducing seizures
AU2016324317A1 (en) 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
JP6968331B2 (ja) * 2016-03-09 2021-11-17 アサフ，ファディ ニューロン性疾患の治療におけるニューロン調節のためのｄｒｅａｄｄの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015136247A1 (en) * 2014-03-13 2015-09-17 Ucl Business Plc Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. M. FORTRESS ET AL: "Designer Receptors Enhance Memory in a Mouse Model of Down Syndrome", THE JOURNAL OF NEUROSCIENCE, vol. 35, no. 4, 28 January 2015, pages 1343 - 1353, XP055679758, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.2658-14.2015 *
ILSE S. PIENAAR ET AL: "Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson's disease", MOL NEURODEGEN, vol. 10, no. 1, 23 September 2015, DOI: 10.1186/s13024-015-0044-5 *

Also Published As

Publication number Publication date
EP3507371A1 (en) 2019-07-10
US20190194287A1 (en) 2019-06-27
EP3507371A4 (en) 2020-08-05
WO2018045178A1 (en) 2018-03-08
AU2017321708A1 (en) 2019-03-14
US11542315B2 (en) 2023-01-03
JP2019526630A (ja) 2019-09-19
US20230174613A1 (en) 2023-06-08
EP3507371B1 (en) 2026-01-28
JP7186702B2 (ja) 2022-12-09
CA3035203A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US20230174613A1 (en) Methods and compositions for treating diseases and disorders of the nervous system
Liao et al. Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin
Sahenk et al. AAV1. NT-3 gene therapy for Charcot–Marie–Tooth neuropathy
Valsecchi et al. miR-206 reduces the severity of motor neuron degeneration in the facial nuclei of the brainstem in a mouse model of SMA
Faustini et al. Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype
Wang et al. Adenosine A2A receptors in the olfactory bulb suppress rapid eye movement sleep in rodents
US20170105980A1 (en) Methods For Treating Nicotinic Acetylcholine Receptor Associated Diseases
Rinker et al. Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models
Kagiava et al. Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy
Castillon et al. The intellectual disability PAK3 R67C mutation impacts cognitive functions and adult hippocampal neurogenesis
Welikovitch et al. Rate of tau propagation is a heritable disease trait in genetically diverse mouse strains
CA3035203C (en) Methods and compositions for treating diseases and disorders of the nervous system
KR102644046B1 (ko) 약물중독 진단용 바이오마커 조성물, 약물중독 치료물질의 스크리닝 방법, 그리고 약물중독 예방 또는 치료용 약학 조성물
Mi et al. Identification of genomic regions regulating Pax6 expression in embryonic forebrain using YAC reporter transgenic mouse lines
de Moura Gomes et al. New MiniPromoter Ple389 (ADORA2A) drives selective expression in medium spiny neurons in mice and non-human primates
AU2020299718B2 (en) cPLA2e inducing agents and uses thereof
Duba-Kiss Developing AAV Gene Therapy Tools for Neurodevelopmental Epileptic Encephalopathies
Huang et al. b-Arrestin-biased b-adrenergic signaling promotes extinction learning of cocaine reward memory
US10426846B2 (en) OLIG1 mini-promoters: PIe305
WO2025175300A1 (en) Compositions and methods for the identification of therapeutics that improve satiety without aversion
WO2023230606A2 (en) Compositions and methods for retinal neuron generation
WO2026021447A1 (zh) 一种M4Di变体以及其治疗疼痛的应用
WO2026021448A1 (zh) 一种M4Di变体以及其治疗癫痫的应用
US9689001B2 (en) NOV mini-promoters
Rivera-Meza The Hyperpolarization-Activated Cyclic Nucleotide-Gated Ion Channels in the Rewarding Effects of Ethanol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)